Drugs / CCX140-B
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03703908 | Oct 2018 → Jun 2020 | focal segmental glomerulosclerosis | Amgen | Terminated | No outcome recorded |
| Phase 2 | NCT03536754 | May 2018 → Feb 2020 | focal segmental glomerulosclerosis | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT01447147 | Oct 2011 → Aug 2014 | diabetic kidney disease, type 2 diabetes mellitus | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT01440257 | Sep 2011 → Feb 2013 | diabetic kidney disease, type 2 diabetes mellitus | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT01028963 | Jan → Oct 2010 | type 2 diabetes mellitus | Amgen | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02003313 Comparator | Nov 2013 → May 2015 | meningitis | Beijing Minhai Biotechnology Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02364830 Comparator | Apr 2013 → Jan 2015 | irritable bowel syndrome | Shiraz University of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCX140-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03536754 ↗ |
| Known as | Colpermin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02364830 ↗ |
| Known as | Group C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02003313 ↗ |
| Action | Inhibit | “The novel CCR2 antagonist CCX140-B” PMID 23986513 ↗ Aug 2013 |
| Modality | Small molecule | — CHEMBL2178573 ↗ |
| Modality | Vaccine | “Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine” NCT02003313 ↗ |
| Route | Oral | “CCX140-B capsules once daily (Group B)” NCT01440257 ↗ |
| Target | CCR2 | “The novel CCR2 antagonist CCX140-B” PMID 23986513 ↗ Aug 2013 |